Price$264.99-6.36 (-2.34%)
2026-01-202026-04-23
News · 26 weeks120+250%
2025-10-262026-04-19
Mix9490d
- Insider72(77%)
- SEC Filings10(11%)
- Other8(9%)
- Leadership2(2%)
- Earnings1(1%)
- Dividends1(1%)
Latest news
25 items- PRLabcorp Launches FDA-Approved Companion Diagnostic to Identify Patients with Ovarian Cancer Eligible for KEYTRUDA®BURLINGTON, N.C., April 22, 2026 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, today announced the nationwide availability of Agilent Technologies' PD-L1 IHC 22C3 pharmDx, the only companion diagnostic approved by the U.S. Food and Drug Administration (FDA) to identify patients with platinum-resistant ovarian cancer who may be eligible for Merck's KEYTRUDA®.i KEYTRUDA (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) are the first FDA-approved PD-1 inhibitors available as part of a complete treatment regimen for eligible patients with platinum-resistant ovarian cancer.ii
- PRLabcorp Launches FDA-Cleared Fentanyl Test Delivering Results in 10 MinutesFirst FDA-cleared rapid fentanyl test of its kind made in the United States designed to help emergency department and hospital teams act quickly when every second countsFentanyl Urine Visual Test is available through Labcorp Point of Care, previously known as MEDTOX DiagnosticsBURLINGTON, N.C., April 15, 2026 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, today announced the launch of the Labcorp Fentanyl Urine Visual Test, the first U.S. Food and Drug Administration (FDA)-cleared rapid fentanyl test of its kind manufactured in the United States. The test delivers results in just 10 minutes, giving healthcare providers fast, actionable
- PRLabcorp Introduces AI-Powered Real-World Data Platform with AWS and Datavant to Accelerate Alzheimer's ResearchPlatform leverages agentic AI and diverse healthcare datasets to transform and speed drug developmentBURLINGTON, N.C., April 14, 2026 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, today announced a new AI-powered real-world data platform, designed to help researchers and biopharmaceutical companies analyze Alzheimer's disease-related data faster. Developed with Amazon Web Services (AWS) and Datavant, the platform provides access to large, diverse datasets and advanced analytics—using deidentified, privacy-protected healthcare data—designed to accelerate scientific discovery, shorten drug development timelines and improve identificatio
- SECSEC Form DEFA14A filed by Labcorp Holdings Inc.DEFA14A - LABCORP HOLDINGS INC. (0000920148) (Filer)
- SECSEC Form DEF 14A filed by Labcorp Holdings Inc.DEF 14A - LABCORP HOLDINGS INC. (0000920148) (Filer)
- SECLabcorp Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - LABCORP HOLDINGS INC. (0000920148) (Filer)
- PRLabcorp Declares Quarterly DividendBURLINGTON, N.C., April 9, 2026 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE:LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock. The dividend will be payable on June 11, 2026, to stockholders of record as of the close of business on May 29, 2026. About LabcorpLabcorp (NYSE:LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident
- SECLabcorp Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - LABCORP HOLDINGS INC. (0000920148) (Filer)
- PRLabcorp to Announce First Quarter Financial Results on April 30, 2026BURLINGTON, N.C., March 31, 2026 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE:LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the first quarter of 2026 before the market opens on Thursday, April 30, 2026. The company will host a webcast beginning at 9:00 a.m. ET that day to discuss the results. The earnings press release and accompanying financial information will be posted on the "News & Events" section of the Labcorp Investor Relations website at https://ir.labcorp.com. A link to the earnings webcast will also be available on the investor relations website.
- INSIDERSEC Form 4 filed by Schechter Adam H4 - LABCORP HOLDINGS INC. (0000920148) (Issuer)
- INSIDERSEC Form 4 filed by Graham Anita Z4 - LABCORP HOLDINGS INC. (0000920148) (Issuer)
- INSIDERSEC Form 4 filed by Schroeder Mark S4 - LABCORP HOLDINGS INC. (0000920148) (Issuer)
- INSIDERSEC Form 4 filed by Caveney Brian J4 - LABCORP HOLDINGS INC. (0000920148) (Issuer)
- INSIDERSEC Form 4 filed by Wilkinson Peter J4 - LABCORP HOLDINGS INC. (0000920148) (Issuer)
- INSIDERSEC Form 4 filed by Vaughn Bryan T4 - LABCORP HOLDINGS INC. (0000920148) (Issuer)
- INSIDERSEC Form 4 filed by Van Der Vaart Sandra D4 - LABCORP HOLDINGS INC. (0000920148) (Issuer)
- INSIDERSEC Form 4 filed by Summy Amy B.4 - LABCORP HOLDINGS INC. (0000920148) (Issuer)
- INSIDERSEC Form 4 filed by Oyegunwa Akinbolade4 - LABCORP HOLDINGS INC. (0000920148) (Issuer)
- INSIDERSEC Form 4 filed by Meltzer Jonathan C4 - LABCORP HOLDINGS INC. (0000920148) (Issuer)
- INSIDERSEC Form 4 filed by Kyle Kathryn W4 - LABCORP HOLDINGS INC. (0000920148) (Issuer)
- INSIDERSEC Form 4 filed by Bailey Megan D.4 - LABCORP HOLDINGS INC. (0000920148) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Labcorp Holdings Inc.SCHEDULE 13G/A - LABCORP HOLDINGS INC. (0000920148) (Subject)
- SECLabcorp Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation8-K - LABCORP HOLDINGS INC. (0000920148) (Filer)
- PRIllumina and Labcorp expand collaboration to broaden access to precision oncology testingSAN DIEGO, March 18, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) and Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, today announced an expanded collaboration to advance precision oncology through innovative applications of next-generation sequencing (NGS) solutions across the healthcare ecosystem. Projects are expected to include promoting equitable access to cancer biomarker testing by bringing it closer to patients through new distributed test offerings; generating evidence to facilitate payer coverage; and developing new tests to address areas of unmet need. "By deepening our collaboration, we'll continue to leverage the strengths of our resp
- PRMiddleby Appoints Glenn Eisenberg To Board of DirectorsThe Middleby Corporation (NASDAQ:MIDD), a global leader in the foodservice industry, today announced the appointment of Glenn Eisenberg to its Board of Directors, effective March 1. With the addition of Mr. Eisenberg, the Middleby Board expands to twelve members. "We are pleased to welcome Glenn Eisenberg to the Middleby Board. His deep experience will be an immediate asset as we execute our strategic transformation," said Tim FitzGerald, Middleby CEO. "Glenn has a proven 20-year track record of success as a public company CFO and senior operating executive across complex global manufacturing businesses. His expertise in financial discipline, industrial manufacturing, capital allocation,